skip to main content
Lingue:

Clinical Evaluation of a Paclitaxel-Eluting Balloon for Treatment of Femoropopliteal Arterial Disease

Micari, Antonio ; Cioppa, Angelo ; Vadalà, Giuseppe ; Castriota, Fausto ; Liso, Armando ; Marchese, Alfredo ; Grattoni, Chiara ; Pantaleo, Paolo ; Cremonesi, Alberto ; Rubino, Paolo ; Biamino, Giancarlo

JACC: Cardiovascular Interventions, March 2012, Vol.5(3), pp.331-338 [Rivista Peer Reviewed]

Fulltext disponibile

Citazioni Citato da
  • Titolo:
    Clinical Evaluation of a Paclitaxel-Eluting Balloon for Treatment of Femoropopliteal Arterial Disease
  • Autore: Micari, Antonio ; Cioppa, Angelo ; Vadalà, Giuseppe ; Castriota, Fausto ; Liso, Armando ; Marchese, Alfredo ; Grattoni, Chiara ; Pantaleo, Paolo ; Cremonesi, Alberto ; Rubino, Paolo ; Biamino, Giancarlo
  • Note di contenuto: OBJECTIVES: This study evaluated the use of a paclitaxel-eluting balloon (PEB) for treatment of femoropopliteal arterial disease.BACKGROUND: Conventional balloon angioplasty and stenting in this setting is associated with high restenosis rates within 12 months. Recent data suggest that PEB use may reduce restenosis. Twelve-month outcomes following PEB use with provisional stenting are described.METHODS: This prospective registry enrolled patients (Rutherford class 2 to 4) with reference vessel diameter of 3 to 7 mm and lesion/occlusion length ≤ 15 cm. Endpoints included primary patency rate, target lesion revascularization, and changes in Rutherford class and ankle-brachial index. Walking capacity, absolute claudication distance, and quality of life were also assessed.RESULTS: The registry enrolled 105 patients. Baseline ankle-brachial index was 0.56 ± 0.15. Baseline Rutherford classification was class 2 or 3 for most patients (91.5%). Most lesions were located in the superficial femoral artery (77.1%). Mean lesion length was 76.3 ± 38.3 mm; 29.8% of lesions were total occlusions. The device was successfully used in all patients and only 12.3% of lesions required stenting. At 12-month follow-up, 92 of 105 patients (87.6%) were evaluable; the primary patency rate was 83.7%; the target lesion revascularization rate was 7.6%; 85.6% of patients were Rutherford class 0 or 1; and mean ankle-brachial index was 0.86 ± 0.15. Quality of life and absolute claudication distance showed significant improvement from baseline to 12-month follow-up.CONCLUSIONS: PEB treatment of femoropopliteal arterial disease resulted in consistent clinical improvement across multiple endpoints with a low rate of stenting and target lesion revascularization.
  • Fa parte di: JACC: Cardiovascular Interventions, March 2012, Vol.5(3), pp.331-338
  • Soggetti: Femoropopliteal Artery ; Ischemic Vascular Disease ; Paclitaxel-Eluting Balloon(S) ; Restenosis ; Medicine
  • Lingua: Inglese
  • Tipo: Articolo
  • Identificativo: ISSN: 1936-8798 ; E-ISSN: 1876-7605 ; DOI: 10.1016/j.jcin.2011.11.010

Ricerca in corso nelle risorse remote ...